Pharmafile Logo

Baxalta

- PMLiVE

Beyond the Data Gap: Primary Research Can Sharpen Real-World Evidence Strategy in Metabolic Care

Metabolic medicine is changing faster than the evidence systems built to track it. New therapies for type 2 diabetes and obesity are reaching more patients, across more indications and through...

KJT Group

- PMLiVE

argenx to acquire Unnatural Products for $1.15bn

argenx already holds a minority stake in UNP and will acquire all remaining shares

- PMLiVE

AbbVie expands Oxford R&D as part of more than £120m investment in UK life sciences

The new site will expand research capabilities across immunology, neuroscience and oncology

- PMLiVE

How pharma companies can use AI to scale personalized engagement without increasing complexity

AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing...

Inizio

- PMLiVE

Creating the conditions for product launch success in a time of volatility

Volatility is reshaping the conditions for successful product launches. Market dynamics can shift quickly, assumptions can change, and teams are increasingly expected to make confident decisions in response.

Inizio

- PMLiVE

Navigating uncertainty in life sciences

The life sciences industry is changing fast. Advances in AI, increasingly complex science, shifting market dynamics and evolving patient needs are creating new challenges for organizations developing and commercializing treatments....

Inizio

- PMLiVE

Inizio appoints Oisín Ó Gógáin as Chief People Officer

Inizio has appointed Oisín Ó Gógáin as Chief People Officer.

Inizio

- PMLiVE

Karyopharm announces planned merger with Ayrmid amid Chapter 11 bankruptcy filing

The merger is not final and other companies will be able to bid for Karyopharm’s assets

- PMLiVE

Novartis presents positive results from two phase 3 trials for relapsing MS

Remibrutinib reduced relapse rates and improved disease progression rates

- PMLiVE

AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

- PMLiVE

Pharma leadership strategies for talent, AI adoption, and continuous learning

In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous...

Inizio

- PMLiVE

Smarter science, sharper strategy: Expert insights from ASCO® 2026

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Inizio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links